Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-079 in Combination With Backbone Regimens for Newly Diagnosed Multiple Myeloma
NCT03984097Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2019
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mezagitamab in multiple myeloma (MM) (3 arms), sponsored by Takeda. Primary endpoints: Recommended Phase 2 Dose, Number of Participants Reporting one or More Serious Adverse Events up to 4 years and 3 more. Started Jul 2019; status: completed.
02
Drugs
mezagitamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03984097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984097.